Effect of oncometabolic surgery on gastric cancer: The remission of hypertension, type 2 diabetes mellitus, and beyond

Table 2 Oncometabolic surgery on hypertension

Ref.	Country	Surgery	Sample size	CR + PR	CR	PR	Follow-up (mo)
Peng et al[15], 2020	China	RYTG, BI, BII, RYGJ	143	55.3%	46.9%	8.4%	6
Wang et al[21], 2014	China	RYTG, RYGJ	16	93.8%	100%	87.5%	12
Park et al[26], 2017	Korea	uRYGJ, LLBR	33	42.4%	NA	NA	12
Kim et al[27], 2019	Korea	RYTG, BI, BII, RYGJ	66	57.6%	45.5%	12.1%	12
Lee et al[28], 2017	Korea	RYTG, BI, BII, RYGJ	351	11.1%	NA	NA	36.7

CR: Complete remission; PR: Partial remission; RYTG: Roux-en-Y total gastrectomy; BII: Billroth II reconstruction; BI: Billroth I reconstruction; RYGJ: Subtotal gastrectomy with Roux-en-Y gastrojejunostomy reconstruction; uRYGJ: Subtotal gastrectomy with uncut Roux-en-Y gastrojejunostomy reconstruction; LLBR: Long-limb bypass reconstruction; NA: Not available.